Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Hp 2 allele linked to histologic response to vitamin E in NASH patients

06 Dec 2019

The haptoglobin (Hp) 2 allele correlates with greater histologic and biological improvement in nonalcoholic steatohepatitis (NASH) with vitamin E treatment as compared with the Hp 1 allele, a study has shown.

“Hp genotype has been linked to oxidative stress and cardiovascular outcomes in response to vitamin E among patients with diabetes mellitus,” the investigators said.

A posthoc analysis was conducted on 228 patients treated with vitamin E or placebo in two clinical trials. The investigators used regression analysis to examine the effect of vitamin E vs placebo, by Hp genotype (1-1, 2-1 or 2-2), on histologic features and laboratory markers of nonalcoholic fatty liver disease, comparing baseline to end-of-treatment values. They also included an interaction term in the regression models to assess differential treatment effect across Hp genotypes.

Hp 2-2 patients who received vitamin E vs placebo had significant histologic improvement (51 percent vs 20 percent; odds ratio [OR], 4.2; p=0.006), resolution of steatohepatitis (44 percent vs 12 percent; OR, 6.2; p=0.009), decrease in nonalcoholic fatty liver disease Activity Score (NAS; –2.2 vs –0.6; p=0.001), and decrease in liver enzymes alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and γ-glutamyl transpeptidase.

Hp 2-1 patients treated with vitamin E vs placebo also demonstrated improved resolution of steatohepatitis, NAS and liver enzymes, whereas Hp 1-1 patients did not show significant improvements in histology or liver enzymes. Vitamin E had no effect on fibrosis stage in any group.

In regression analysis, having Hp 2-2 or 2-1 showed incremental benefit for all liver enzymes as compared with having Hp 1-1.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.